Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Sarcoma 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Liposarcoma 1Carcinoma in Situ 1

Interventions

pembrolizumab 610Carboplatin 375Paclitaxel 283Cisplatin 268Gemcitabine 256Pemetrexed 194Bevacizumab 191Nivolumab 190Docetaxel 190Injections 169Cyclophosphamide 148atezolizumab 138Capecitabine 134Fluorouracil 133Oxaliplatin 132Dexamethasone 129Fulvestrant 115durvalumab 114130-nm albumin-bound paclitaxel 111fludarabine 102Cetuximab 101Leucovorin 97Rituximab 96venetoclax 90Lenalidomide 84Prednisone 79enzalutamide 78Azacitidine 76Irinotecan 74Ipilimumab 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Clinical Trials, Phase I as Topic × 1 year × Clear all
NCT01171898 2026-05-11

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Aragon Pharmaceuticals, Inc.

Phase 1/2 Completed
127 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

NCT04752722 2026-04-30

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

enGene, Inc.

Phase 1/2 Recruiting
350 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT06578624 2025-06-05

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

Lamassu Bio Inc

Phase 1/2 Recruiting
70 enrolled
Sarcoma

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡